Literature DB >> 27601953

Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Meritxell Arenas1, Sebastià Sabater2, Pedro Lara Jiménez3, Àngels Rovirosa4, Albert Biete4, Victoria Linares5, Montse Belles5, Julià Panés6.   

Abstract

Immunomodulatory effects of low-dose radiotherapy (LD-RT) have been used for the treatment of several benign diseases, including arthrodegenerative and inflammatory pathologies. Graves' disease is an autoimmune disease and radiotherapy (RT) is a therapeutic option for ocular complications. The dose recommended in the clinical practice is 20 Gy (2 Gy/day). We hypothesized that lower doses (<10 Gy total dose, <1 Gy/day) could results in higher efficacy if we achieved anti-inflammatory and immunomodulatory effects of LD-RT. We review current evidence on the effects of RT in the treatment of Graves' disease and the possible use of LD-RT treatment strategy.

Entities:  

Keywords:  Graves’ ophthalmopathy; Low-dose radiotherapy; Radiotherapy for benign disease

Year:  2016        PMID: 27601953      PMCID: PMC5002018          DOI: 10.1016/j.rpor.2016.02.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  49 in total

1.  Mononuclear cell adhesion and cell adhesion molecule liberation after X-irradiation of activated endothelial cells in vitro.

Authors:  G Hildebrandt; L Maggiorella; F Rödel; V Rödel; D Willis; K-R Trott
Journal:  Int J Radiat Biol       Date:  2002-04       Impact factor: 2.694

2.  Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.

Authors:  Daniel El Fassi; Claus H Nielsen; Hans C Hasselbalch; Laszlo Hegedüs
Journal:  Thyroid       Date:  2006-07       Impact factor: 6.568

3.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

4.  Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids.

Authors:  J Myśliwiec; A Kretowski; M Szelachowska; J Topolska; A Mikita; I Kinalska
Journal:  Immunol Lett       Date:  2001-10-01       Impact factor: 3.685

5.  Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy.

Authors:  Y Hiromatsu; D Yang; T Bednarczuk; I Miyake; K Nonaka; Y Inoue
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

6.  Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.

Authors:  Pari N Shams; Roy Ma; Tom Pickles; Jack Rootman; Peter J Dolman
Journal:  Am J Ophthalmol       Date:  2014-02-26       Impact factor: 5.258

Review 7.  Graves' ophthalmopathy: a rational approach to treatment.

Authors:  Wilmar M Wiersinga; Mark F Prummel
Journal:  Trends Endocrinol Metab       Date:  2002-09       Impact factor: 12.015

8.  Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

Review 10.  Immune mechanisms in thyroid eye disease.

Authors:  Geniece M Lehmann; Steven E Feldon; Terry J Smith; Richard P Phipps
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

View more
  2 in total

Review 1.  Review of the treatment of Graves' ophthalmopathy: The role of the new radiation techniques.

Authors:  Iñigo San Miguel; Meritxell Arenas; Ruth Carmona; Joaquin Rutllan; Francisco Medina-Rivero; Pedro Lara
Journal:  Saudi J Ophthalmol       Date:  2017-09-21

2.  Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.

Authors:  Mira Park; J Paul Banga; Gi Jin Kim; MinYoung Kim; Helen Lew
Journal:  Stem Cell Res Ther       Date:  2019-08-09       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.